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Abstract Parafibromin is a protein encoded by the
hyperparathyroidism 2 oncosuppressor gene and its down-
regulated expression is involved in pathogenesis of
parathyroid carcinomas. To clarify the roles of parafibro-
min expression in tumourigenesis and progression of
gastric carcinomas, it was examined by immunohistochem-
istry (IHC) on tissue microarray containing gastric carci-
nomas (n=508), adenomas (n=45) and gastritis (n=49)
with a comparison of its expression with clinicopatholog-
ical parametres of carcinomas. Gastric carcinoma cell lines
(MKN28, AGS, MKN45, KATO-III and HGC-27) were
studied for parafibromin expression by IHC and western
blot. Parafibromin expression was localised in the nucleus
of gastric epithelial cells, adenoma, carcinoma cells and cell
lines. Its expression was gradually decreased from gastritis
to gastric carcinoma, through gastric adenomas (p<0.05)
and inversely correlated with tumour size, depth of
invasion, lymphatic invasion, lymph node metastasis and
Union Internationale Contre le Cancer (UICC) staging (p<
0.05) but not with sex or venous invasion (p>0.05).
Parafibromin was strongly expressed in older carcinoma
patients compared with younger ones (p<0.05). There was
stronger positivity of parafibromin in intestinal-type than
diffuse-type carcinomas (p<0.05). Univariate analysis
indicated cumulative survival rate of patients with positive
parafibromin expression to be higher than without its
expression (p<0.05). Multivariate analysis showed that
age, tumour size, depth of invasion, lymphatic invasion,
lymph node metastasis, UICC staging and Lauren’s
classification but not sex, venous invasion or parafibromin
expression were independent prognostic factors for carci-
nomas(p<0.05). Downregulated parafibromin expression
possibly contributed to pathogenesis, growth, invasion and
metastasis of gastric carcinomas. It was considered as a
promising marker to indicate the aggressive behaviours and
prognosis of gastric carcinomas.
Keywords Gastric carcinoma . Parafibromin .
Pathogenesis . Progression . Prognosis
Introduction
Parafibromin is a protein encoded by the hyperparathyroidism
2 (HRPT2) oncosuppressor gene, whose mutation causes the
hyperparathyroidism–jaw tumour syndrome. The disease is an
autosomal dominant disorder characterised by the occurrence
of parathyroid adenoma or carcinoma, fibro-osseous jaw
tumours of the mandible or maxilla and renal neoplastic and
non-neoplastic abnormalities, such as Wilms’ tumour, hamar-
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toma or cystic renal disease [1, 16, 20]. HRPT2 gene is
located in human chromosome 1q31.2, consists of 17 exons
and spans 18.5 kb in the genome. It encodes a 2.7-kb
transcript which is translated into a 531-amino-acid parafi-
bromin protein with a molecular weight of 60 kd [3, 4, 23].
The 200-amino-acid C-terminal segment of parafibromin
shares 32% identity and 54% homology with cell division
cycle 73, a Saccharomyces cerevisiae protein forming the
polymerase-associated factor 1 (Paf1) complex, which is
associated with ribonucleic acid (RNA) polymerase II and
involved in transcript site selection, transcriptional elonga-
tion, histone H2B ubiquitination, histone H3 methylation,
poly (A) length control and coupling of transcriptional and
posttranscriptional events [10, 17, 18, 24, 27]. Parafibromin
overexpression was documented to inhibit colony formation
and cellular proliferation and induce cell cycle arrest in the
G1 phase, indicating that parafibromin has a critical role in
cell growth [28]. Northern blot analysis showed HRPT2
expression in heart, brain, placenta, lung, liver, skeletal
muscle, kidney and pancreas [4]. Western blot study revealed
parafibromin expression as a 60-kd band in the adrenal
gland, heart, pancreas and kidney but 40-kd immunoreactive
bands in the heart and skeletal muscle of human [25].
Immunohistochemically, higher expression of parafibromin
was found widespread in glomerular mesangial cell, hepa-
tocytes, cells of the base of gastric glands, renal cortex
tubules and the pars intermedia of the hypophysis [17].
Subsequent investigations have revealed that mutations in
HRPT2 are present in 66–100% of sporadic parathyroid
carcinomas [7, 20]. Hyperparathyroidism–jaw-tumours-
syndrome-related and sporadic parathyroid carcinomas are
characterised by loss of parafibromin nuclear immunoreac-
tivity [5, 22]. Selvarajan et al. [19] found that parafibromin
expression was inversely linked to tumour size, pathologic
stage and lymphovascular invasion of breast carcinomas using
immunohistochemistry in a tissue microarray (TMA) study.
These findings suggested the potential roles of parafibromin
in pathogenesis and progression of malignancies.
Gastric carcinoma ranks as the world's second leading
cause of cancer mortality behind lung cancer despite a
sharp worldwide decline in both its incidence and mortality
since the second half of the 20th century [9]. Tumouri-
genesis and progression of gastric carcinoma is a multistage
process with the involvement of a multifactorial aetiology,
which mainly results from gene–environment interactions
[32, 33]. Gastric carcinomas are classified into early and
advanced ones on the basis of whether the carcinomas
invade into the muscularis propria of the stomach [12]. In
1965, Lauren [13] classified gastric carcinomas into
intestinal- and diffuse-type ones based on the morpholog-
ical appearances. Intestinal-type carcinomas are character-
ised by cohesive carcinoma cells forming gland-like tubular
structures with expanding or infiltrative growth pattern.
However, the cell cohesion is less apparent or absent in
diffuse-type carcinoma and cancer cells diffusely spread in
the gastric wall [31]. Generally, there is a favorable
prognosis for the patients with early or intestinal carcinoma
compared with the other type. In our study, parafibromin
expression was examined in gastric carcinoma, adenoma,
gastritis and gastric carcinoma cell lines and compared with
the clinicopathological parametres of carcinomas, as well as
prognosis to explore the clinicopathological significance
and molecular roles of parafibromin expression in stepwise
development of gastric carcinoma.
Materials and methods
Subjects
Gastric carcinomas (n=508) were collected from the
surgical resection, adenoma (n=45) from endoscopic
biopsy or polypectomy and gastritis (n=49) from the
endoscopic biopsy in our affiliated hospital, Himi Citizen
Hospital and Kouseiren Takanoka Hospital between 1993
and 2006. All carcinomas were adenocarcinomas and the
adenoma group was free from non-neoplastic polyp types,
leiomyomas and benign gastrointestinal stromal tumours.
The patients with gastric carcinoma were 354 men and 154
women (29~91 years, mean=65.4 years). Among them,
191 cases have carcinomas accompanied with lymph node
metastasis. None of the patients underwent chemotherapy
or radiotherapy before surgery. They all provided consent
for use of tumour tissue for clinical research and our
University Ethical Committee approved the research proto-
col. We followed up all patients by consulting their case
documents or through telephone.
Pathology
All tissues were fixed in 4% neutralised formaldehyde,
embedded in paraffin and incised into 4-μm sections. These
sections were stained by haematoxylin and eosin (HE) to
confirm their histological diagnosis and other microscopic
characteristics. The staging for each gastric carcinoma was
evaluated according to the Union Internationale Contre le
Cancer (UICC) system for the extent of tumour spread [21].
Histological architecture of gastric carcinoma was
expressed in terms of Lauren’s [13, 31] classification.
Furthermore, tumour size, depth of invasion, lymphatic and
venous invasion were determined.
Tissue microarray
Representative areas of solid tumours were identified in HE-
stained sections of the selected tumour cases and a 2-mm-in-
148 Virchows Arch (2008) 452:147–155
diametre tissue core per donor block was punched out and
transferred to a recipient block with a maximum of 48 cores
using a Tissue Microarrayer (AZUMAYA KIN-1, Japan).
Four-micrometre-thick sections were consecutively incised
from the recipient block and transferred to polylysine-coated
glass slides. HE staining was performed on TMA for
confirmation of tumour tissue.
Cell lines and culture
Gastric carcinoma cell lines come from the Japanese
Physical and Chemical Institute, including MKN28 (well-
differentiated adenocarcinoma), AGS (moderately differen-
tiated adenocarcinoma), MNK45 (poorly differentiated
adenocarcinoma), KATO-III (poorly differentiated adeno-
carcinoma) and HGC-27 (undifferentiated adenocarcino-
ma). They were maintained in Roswell Park Memorial
Institute 1640 (MKN28, MKN45 and KATO-III), minimum
essential (HGC-27) or Ham’s F12 (AGS) medium supple-
mented with 10% foetal bovine serum, 100-units/ml
penicillin, and 100-μg/ml streptomycin in a humidified
atmosphere of 5% CO2 at 37°C. Total protein was prepared
from all cells by cell disruption buffer according to Protein
And RNA Isolation System manual (Arctiris Bioscience,
USA). All cells were collected by centrifugation, rinsed
with phosphate-buffered saline, fixed by 10% formalin and
then embedded in paraffin as routinely processed.
Immunohistochemistry
Consecutive sections were deparaffinised with xylene,
dehydrated with alcohol and subjected to antigen retrieval
by irradiating in target retrieval solution citrate pH 6.0
(TRS, DAKO, Carpinteria, CA 93013, USA) for 15 min
with microwave oven (Oriental Rotor Lmt. Co., Tokyo,
Japan). Five percent bovine serum albumin was then
applied for 1 min to prevent non-specific binding. The
sections were incubated with mouse anti-parafibromin
antibody (Clone 2H1, SC-33638, Santa Cruz, CA, USA;
1:40) for 15 min, then treated with the anti-mouse Envison-
PO (DAKO, CA, USA) antibody for 15 min. Binding sites
were visualised with 3, 3′-diaminobenzidine with the 5-min
reaction. All the incubations were performed in a micro-
wave oven to allow intermittent irradiation as described
previously [11]. After each treatment, the slides were
washed with Tris-buffered saline with Tween 20 (TBST;
10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20) three
times for 1 min. After being counterstained with Mayer’s
haematoxylin, the sections were dehydrated, cleared and
mounted. Omission of the primary antibody was used as a
negative control.
One hundred cells were randomly selected and counted
from five representative fields of each section blindly by
three independent observers (Takano Y, Li XH and Zheng
HC). The positive percentage of counted cells was graded
semi-quantitatively according to a four-tier scoring system:
negative (−), 0~5%; weakly positive (+), 6~25%; moder-
ately positive (++), 26~50%; and strongly positive (+++),
51~100%.
Western blot
Fifty-microgramme denatured protein was separated on an
SDS-polyacrylamide gel (10% acrylamide) and transferred
to Hybond membrane (Amersham, Germany), which was
then blocked overnight in 5% milk in TBST. For
immunoblotting, the membrane was incubated for 1 h with
mouse anti-parafibromin antibody as described above.
Then, it was rinsed by TBST and incubated with anti-
mouse immunoglobulin G conjugated to horseradish per-
oxidase (DAKO, CA, USA, 1:1,000) for 1 h. Bands were
visualised with X-ray film (Fujifilm, Japan) by ECL-Plus
detection reagents (Amersham, Germany). After that,
membrane was washed with WB Stripping Solution (pH
2–3, Nacalai, Tokyo, Japan) for 30 min and treated as
described above except mouse anti-β-actin antibody (Sigma,
MO, USA, 1:5,000) as an internal control.
Statistical analysis
Statistical evaluation was performed using Spearman corre-
lation test to analyse the rank data. Kaplan–Meier survival
plots were generated and comparisons between survival
curves were made with the log–rank statistic. The Cox’s
proportional hazards model was employed for multivariate
analysis. P<0.05 was considered as statistically significant.
SPSS 10.0 software was employed to analyse all data.
Results
Parafibromin expression in gastric tumours and carcinoma
cell lines
As shown in Fig. 1, parafibromin was positively immunos-
tained in the nucleus of MKN28, AGS, MKN45, KATO-III
and HGC-27, and its expression level was consistent with
the data of Western blot. Parafibromin was strongly
expressed in the nucleus of gastric epithelial cells,
adenomas and early carcinomas but not in given advanced
carcinomas. Occasionally, it also appeared in stromal
fibroblasts and lymphocytes but much weaker than epithe-
lial cells or adenomas (Fig. 2).Generally, the stromal
lymphocytes and fibroblasts were negative in cases where
the tumour was negative. Overall, parafibromin expression
was detected respectively in all gastritis (100.0%), 36 out of
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45 adenoma patients (80.0%) and 233 out of total 508
gastric carcinoma patients (45.9%). Statistically, gradually
reduced expression of parafibromin was seen from gastritis
to gastric carcinoma through gastric adenoma (p<0.05,
Table 1). As summarised in Table 2, parafibromin expres-
sion was inversely correlated with tumour size, depth of
invasion, lymphatic invasion, lymph node metastasis and
UICC staging (p<0.05) but not with sex or venous invasion
(p>0.05). Parafibromin was strongly expressed in older
carcinoma patients compared with younger ones (p<0.05).
Intestinal-type carcinomas exhibited more frequent expres-
sion of parafibromin than diffuse-type ones (p<0.05).
Fig. 1 Parafibromin expression in gastric carcinoma cell lines. a
Parafibromin was positively immunostained in the nucleus of MKN28
(a), AGS (b), MKN45 (c), KATO-III (d) and HGC-27(e). b Cell lysate
(50 µg) was loaded and probed with anti-human parafibromin
antibody (60 kd) with β-actin (42 kd) as an internal control. Lane
#1: MKN28; #2 AGS; #3 MKN45; #4 KATO-III; #5 HGC-27
Fig. 2 Immunohistochemical
staining of parafibromin in gas-
tritis, adenoma and carcinoma.
Note parafibromin positivity
was strongly observed in the
nucleus of gastric superficial
epithelium (a), and adenoma (c)
and early gastric carcinoma (b),
occasionally weaker in the stro-
mal fibroblasts and lymphocytes
(a, c), but not in given advanced
gastric carcinomas (d), indicat-
ing that the internal positive
control (stromal cells) was neg-
ative adjacent to the negative
staining carcinoma cells but
positive adjacent to the positive
epithelial cells
150 Virchows Arch (2008) 452:147–155
Univariate and multivariate survival analysis
Follow-up information was available on 508 gastric
carcinoma patients for periods ranging from 0.2 months to
12.2 years (median=67.2 months). Figure 3 showed
survival curves stratified according to parafibromin expres-
sion for gastric carcinomas. Univariate analysis using the
Kaplan–Meier method indicated cumulative survival rate of
patients with weak, moderate or strong parafibromin
expression to be obviously higher than without its expres-
sion (p<0.05; Fig. 3a). The significant difference disap-
peared if stratified according to the depth of invasion
(Fig. 3b, c). Multivariate analysis using Cox’ s proportional
hazard model indicated that age, tumour size, depth of
invasion, lymphatic invasion, lymph node metastasis, UICC
staging and Lauren’s classification (p<0.05) but not sex,
Table 2 Relationship between parafibromin expression and clinicopathological features of gastric carcinomas
Clinicopathological features Number Parafibromin expression
− + ++ +++ PR (%) Rs p value
Age (years)
<65 209 125 24 24 36 40.2 0.095 <0.05
≥65 299 150 31 36 82 49.8
Sex
Male 354 188 37 38 91 46.9 0.054 >0.05
Female 154 87 18 22 27 43.5
Tumour size (cm)
<4 263 116 26 34 85 55.9 −0.237 <0.001
≥4 245 159 27 26 33 35.1
Depth of invasion
Tis−1 263 102 30 40 91 61.2 −0.344 <0.001
T2-4 245 173 25 20 27 29.4
Lymphatic invasion
− 331 157 42 45 87 52.6 −0.168 <0.001
+ 177 118 13 15 31 33.3
Venous invasion
− 443 236 49 51 107 46.7 −0.051 >0.05
+ 65 39 6 9 11 40.0
Lymph node metastasis
− 317 138 38 44 97 56.5 −0.285 <0.001
+ 191 137 17 16 21 28.3
UICC staging
0–I 292 123 36 41 92 57.9 −0.292 <0.001
II-IV 216 152 19 19 26 29.6
Lauren’s classification
Intestinal-type 273 108 34 38 93 60.4 −0.322 <0.001
Diffuse-type 225 157 21 22 25 30.2
PR Positive rate, Tis carcinoma in situ, T1 lamina propria and submucosa, T2 muscularis propria and subserosa, T3 exposure to serosa, T4 invasion
into serosa, UICC Union Internationale Contre le Cancer
Table 1 Parafibromin expression in gastric tissue samples
Groups Number Parafibromin expression
− + ++ +++ PR (%)
Gastritis 49 0 1 7 41 100.0a
Gastric adenoma 45 9 5 8 23 80.0b
Gastric carcinoma 508 275 55 60 118 45.9
PR Positive rate
a Compared with gastric adenoma or carcinoma, p<0.001
b Compared with gastric carcinoma, p<0.001
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venous invasion or parafibromin expression were indepen-
dent prognostic factors for overall gastric carcinomas
(p>0.05; Table 3).
Discussion
HRPT2 has been isolated from complementary DNA
libraries of parathyroid, kidney and bone tissue and encodes
tumour suppressor protein parafibromin [4]. In the present
study, the nuclear expression pattern was observed in the
gastric epithelial cells, adenomas, adenocarcinomas and
carcinoma cell lines consistent with previous reports in the
gastric superficial mucosa, hepatocytes, kidney cortex
tubules, adrenal gland, spleen lymphocytes, parathyroid
tissue, adenoma and carcinomas, breast carcinoma [5, 8, 17,
19]. Although the result was in contrast with the paper of
Porzionato et al. [17] possibly due to different incubation
times of primary antibody, the great majority of immuno-
histochemical and cell transfection studies supported our
observation of the nuclear staining [2, 5, 6, 8, 14, 19]. This
study again demonstrates that parafibromin is nuclear and
not cytoplasmic or nucleocytoplasmic in location as
initially thought. The weaker expression of parafibromin
in stromal cells than epithelial cells and adenoma might be
due to the specificity of its cellular distribution as described
previously [17]. It was found that the translocation of
parafibromin to the nuclear compartment involved a
function monopartite nuclear localisation signal at residues
136–139 [2, 6]. Parafibromin is a component of Paf1
complex in the nucleus, where it plays a role in cell cycle
regulation, histone methylation, lipid and nucleic acid metab-
olism [10, 17]. The distribution pattern of parafibromin
protein in gastric epithelial cells or tumour cells demonstrated
its biological function in the nucleus.
Statistically, parafibromin expression was gradually
reduced from gastritis to carcinoma through adenoma in
line with parathyroid carcinogenesis, suggesting that down-
regulated parafibromin expression might contribute to the
malignant transformation of gastric epithelial cells as an
early event. The positive rate of parafibromin expression was
reduced to 80% in gastric adenoma and reached about 46% of
gastric adenocarcinoma, supporting the involvement of
parafibromin in the gastric adenoma–adenocarcinoma se-
quence. Actually, the adenoma can progress into and be
incorporated with gastric well-differentiated carcinoma when
it grows bigger and de novo carcinogenesis is well under-
stood, especially in diffuse-type gastric carcinomas [34].
Higher parafibromin expression in adenoma and intestinal-
type carcinoma indicated that decreased parafibromin
expression might play an important role in de novo diffuse-
type carcinogenesis but less in intestinal carcinogenic
pathway.
A body of evidences indicated that downregulation of
tumour suppressor protein expression was due to genetic or
epigenetic changes, like allelic loss, mutation, loss of
heterozygosity (LOH), hypermethylation and microsatellite
instability in malignancies [29, 30]. In the sporadic
parathyroid carcinomas and hyperparathyroidism–jaw
tumours, LOH or mutation of HRPT2 might cause the loss
and inactivation of parafibromin protein [20, 25, 26].
Furthermore, the reduced expression of parafibromin was
Fig. 3 Correlation between parafibromin status and prognosis of the
gastric carcinoma patients. Kaplan–Meier curves for cumulative
survival rate of patients with gastric carcinomas according to the
parafibromin expression in overall (a), early (b, EGC) and advanced
(c, AGC) gastric carcinomas
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found to closely link to the tumour size, depth of invasion,
lymphatic or venous invasion and UICC staging in line
with the observation in breast carcinomas [19], indicating
the inhibitory effects of parafibromin on tumour growth,
invasion, metastasis and progression of gastric carcinomas.
Drosophila Hyrax and its human orthologue, parafibromin,
are required for nuclear transduction of the Wnt/Wg signal
and bind directly to the C-terminal region of beta-catenin–
Armadillo, thereby controlling transcriptional initiation and
elongation by RNA polymerase II [15]. Parafibromin
overexpression can inhibit colony formation, anchorage-
dependent cell growth and cellular proliferation and induce
cell cycle arrest in the G1 phase [28]. These findings
demonstrated that loss of parafibromin expression had
impact on the pathogenesis and progression of malignan-
cies by promoting cellular proliferation. Additionally,
parafibromin was expressed with a higher incidence in
intestinal-type gastric cancer, which is presumed to arise
from preceding dysplastic lesions, than diffuse-type one,
which evolves without any precedent dysplastic changes. It
is also demonstrated that distinct parafibromin expression
underlies the molecular mechanisms for the differentiation
of intestinal- and diffuse-type carcinomas.
Until now, there is yet no paper describing the prognostic
significance of parafibromin expression in malignancies.
Here, for the first time, we analysed the relation of
parafibromin expression with the survival rate of 508 patients
with gastric carcinoma. The results revealed a close link
between its loss and worse survival. If stratified according to
the depth of invasion, the significant link disappeared,
indicating that the relationship between parafibromin expres-
sion and prognosis depends on the depth of invasion. The
multivariate analysis demonstrated that age, depth of inva-
sion, lymphatic invasion, lymph node metastasis, UICC
staging and Lauren’s classification but not parafibromin
expression, venous invasion or sex were independent
prognostic factors for carcinomas. These findings suggested
that parafibromin expression is a promising indicator for the
favorable prognosis of gastric carcinoma patients, albeit not
independent.
In the present study, a large number of gastric carcinoma
cases were screened by TMA, which takes the advantages
of high throughput, identical immunohistochemical con-
ditions, and economy of samples, antibodies and time [33].
Although we used 2-mm-in-diametre needles, which are
large enough to evaluate the morphological appearance and
carefully selected representative regions with the reference
of HE slides, it was difficult to avoid selection bias. Gill
et al. [5] found that stronger parafibromin staining and
more positive cells sometimes appeared at the edges of the
parathyroid tumour than in the centre. This could be due to
fixation methods, other processing issues or a biological
phenomenon, for example tissue hypoxia in the centre of
large tumours. Additionally, the collection of our samples
(e.g. gastritis, adenoma and adenocarcinoma) respectively
from the endoscopic biopsy, polypectomy, or surgical
resection put forward their another possibility of selection
bias because of different fixation and processing methods.
Selvarajan et al. [19] found that parafibromin underexpres-
sion was correlated particularly with large tumour size
which is in line with our finding. It was possible that
weaker staining could be attributable to poor fixation
properties in the centre of large tumours. Because tumour
size is a key prognostic indicator, this artifact could explain
the prognostic significance of parafibromin in gastric
carcinomas. Therefore, it is a limitation of the present
study not to separate the edge and centre of gastric
carcinomas when establishing TMA. In the current study,
the negatively staining carcinomas are associated with a
negative internal control (stromal cells and lymphocytes)
whereas the positive staining epithelium is adjacent to
positive staining internal controls. Therefore, the negative
staining of the carcinoma might be artificial, which should
be considered as another limitation of the study. Our study
might be mentioned as a preliminary experiment and the
staining with original-size sections is an extensive work in
Table 3 Multivariate analysis of clinicopathological variables for survival with gastric carcinomas
Number Clinicopathological parametres Relative risk (95%CI) p value
A Age (≥65 years) 1.929 (1.357–2.743) <0.001
B Sex (female) 1.463 (0.983–2.179) >0.05
C Tumour size (≥4 cm) 1.606 (1.013–2.547) <0.05
D Depth of invasion (T2–4) 6.530 (3.110–13.710) <0.001
E Lymphatic invasion (+) 2.626 (1.516–3.374) <0.001
F Venous invasion (+) 0.959 (0.633–1.452) >0.05
G Lymph node metastasis (+) 2.773 (1.525–5.043) <0.01
H UICC staging (II-IV) 0.294 (0.139–0.622) <0.01
I Lauren’s classification (diffuse-type) 1.796 (1.212–2.661) <0.01
J Parafibromin expression (+~+++) 0.792 (0.529–1.187) >0.05
CI Confidence interval, UICC= Union Internationale Contre le Cancer
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the future using the gastric carcinoma samples, fixed and
processed by the same approach.
In summary, downregulated parafibromin expression
might play an important role in malignant transformation
of gastric epithelial cells. Its reduced expression was
closely related to growth, invasion, metastasis and worse
prognosis of gastric carcinomas. Its expression could be
employed to differentiate the intestinal- and diffuse-type
carcinomas and underlay the molecular mechanism about
the differentiation of both carcinomas. It was considered as
a promising marker to indicate the pathobiological behav-
iours and prognosis of gastric carcinomas.
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